Healthcare Industry News:  Restylane 

Devices Regulatory

 News Release - September 12, 2006

Q-Med: Q-Med's First Product in the Field of Body Augmentations, MACROLANE, Approved in Europe

STOCKHOLM, Sweden--(HSMN NewsFeed)--Sept. 12, 2006--Q-Med's (STO:QMED) product MACROLANE has received a CE certification for the indication concave body deformities.

MACROLANE is the first product approved to be used in the field of body augmentations, for example asymmetries after liposuction. The approval is an important step in the development of the product and MACROLANE will now be further documented together with leading plastic surgeons in the field.

"This is very exciting but calls for a careful clinical exploration of the different techniques and indications that will best serve the purpose of our patients" says Bengt Agerup, CEO.

MACROLANE is an esthetic treatment for the correction of body concave deformities, for example asymmetries after liposuction. MACROLANE is based on Q-Med's patented NASHA technology. Q-Med continues to explore and develop different versions of MACROLANE, for example for breast tissue augmentation.

Q-Med is a rapidly growing and profitable biotechnology/medical device company. The company develops, produces, markets and sells implants for esthetic and medical use. All products are based on the company's patented technology for the production of stabilized non-animal hyaluronic acid, NASHA(TM). The product portfolio today contains: Restylane, for the filling out of lips and facial wrinkles and for facial contouring; DUROLANE, for the treatment of osteoarthritis of the hip and knee joints; DEFLUX, for the treatment of vesicoureteral reflux (a malformation of the urinary bladder) in children and ZUIDEX, for the treatment of stress urinary incontinence in women. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 580 co-workers, with approximately 380 at the company's head office and production facility in Uppsala, Sweden. The Q-Med share is listed on the O-list of the Stockholm Stock Exchange.

NASHA, DUROLANE, ZUIDEX, IMPLACER, DEFLUX and all product names within the Restylane family are trademarks that belong to Q-Med.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.

Source: Q-Med

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.